Free Trial

Monopar Therapeutics (MNPR) Stock Price, News & Analysis

Monopar Therapeutics logo
$98.64 +1.43 (+1.47%)
As of 03:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Advanced

Key Stats

Today's Range
$94.62
$100.57
50-Day Range
$30.42
$97.21
52-Week Range
$4.50
$101.06
Volume
52,575 shs
Average Volume
43,051 shs
Market Capitalization
$608.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.44
Consensus Rating
Buy

Company Overview

Monopar Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

MNPR MarketRank™: 

Monopar Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 771st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Monopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Downside Risk

    Monopar Therapeutics has a consensus price target of $90.44, representing about 9.0% downside from its current price of $99.34.

  • Amount of Analyst Coverage

    Monopar Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Monopar Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Monopar Therapeutics are expected to decrease in the coming year, from ($1.65) to ($2.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monopar Therapeutics is -29.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monopar Therapeutics is -29.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Monopar Therapeutics has a P/B Ratio of 11.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Monopar Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.72% of the float of Monopar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monopar Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Monopar Therapeutics has recently increased by 7.70%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Monopar Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Monopar Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.72% of the float of Monopar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monopar Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Monopar Therapeutics has recently increased by 7.70%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Monopar Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for Monopar Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Monopar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,700,227.00 in company stock.

  • Percentage Held by Insiders

    20.50% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.83% of the stock of Monopar Therapeutics is held by institutions.

  • Read more about Monopar Therapeutics' insider trading history.
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MNPR Stock News Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
HC Wainwright Has Strong Forecast for MNPR FY2027 Earnings
Analysts Issue Forecasts for MNPR Q1 Earnings
MNPR FY2025 EPS Estimate Lifted by Cantor Fitzgerald
See More Headlines

MNPR Stock Analysis - Frequently Asked Questions

Monopar Therapeutics' stock was trading at $22.00 on January 1st, 2025. Since then, MNPR shares have increased by 351.6% and is now trading at $99.3440.

Monopar Therapeutics Inc. (NASDAQ:MNPR) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12.

Shares of Monopar Therapeutics reverse split on the morning of Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Monopar Therapeutics subsidiaries include Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.

Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Tonix Pharmaceuticals (TNXP) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
8/12/2025
Today
10/03/2025
Next Earnings (Estimated)
11/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MNPR
CIK
1645469
Fax
N/A
Employees
10
Year Founded
2014

Price Target and Rating

High Price Target
$115.00
Low Price Target
$50.00
Potential Upside/Downside
-7.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.59 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41.76%
Return on Assets
-39.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
33.93
Quick Ratio
33.93

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.02 per share
Price / Book
10.88

Miscellaneous

Outstanding Shares
6,170,000
Free Float
4,905,000
Market Cap
$605.34 million
Optionable
Not Optionable
Beta
1.42

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:MNPR) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners